Beaudart, Charlotte ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie clinique
Locquet, Médéa ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie clinique
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Delandsheere, Laura ; Université de Liège - ULiège > Master sc. santé publ., à finalité
Petermans, Jean ; Université de Liège - ULiège > Département des sciences cliniques > Gériatrie
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Language :
English
Title :
Quality of life in sarcopenia measured with the SarQoL®: impact of the use of different diagnosis definitions
Beaudart C, Zaaria M, Pasleau F et al (2017) Health outcomes of sarcopenia: a systematic review and meta-analysis. PLoS One 12:e0169548. https://doi.org/10.1371/journal.pone.0169548
Lang T, Streeper T, Cawthon P et al (2010) Sarcopenia: etiology, clinical consequences, intervention, and assessment. Osteoporos Int 21:543–559. https://doi.org/10.1007/s00198-009-1059-y
Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing 39:412–423. https://doi.org/10.1093/ageing/afq034
Cesari M, Landi F, Calvani R et al (2017) Rationale for a preliminary operational definition of physical frailty and sarcopenia in the SPRINTT trial. Aging Clin Exp Res 29:81–88. https://doi.org/10.1007/s40520-016-0716-1
Rizzoli R, Reginster JY, Arnal JF et al (2013) Quality of life in sarcopenia and frailty. Calcif Tissue Int 93:101–120. https://doi.org/10.1007/s00223-013-9758-y
Beaudart C, Biver E, Bruyère O et al (2017) Quality of life assessment in musculo-skeletal health. Aging Clin Exp Res. https://doi.org/10.1007/s40520-017-0794-8
Beaudart C, Biver E, Reginster J-Y et al (2015) Development of a self-administrated quality of life questionnaire for sarcopenia in elderly subjects: the SarQoL. Age Ageing 44:960–966. https://doi.org/10.1093/ageing/afv133
Beaudart C, Biver E, Reginster J-Y et al (2016) Validation of SarQoL®, a specific health-related quality of life questionnaire for sarcopenia. J Cachexia Sarcopenia Muscle. https://doi.org/10.1002/jcsm.12149
Beaudart C, McCloskey E, Bruyère O et al (2016) Sarcopenia in daily practice: assessment and management. BMC Geriatr 16:170. https://doi.org/10.1186/s12877-016-0349-4
Ildiko GA, Gabriela M, Charlotte B et al (2017) Psychometric performance of the Romanian version of the SarQoL®, a health-related quality of life questionnaire for sarcopenia. Arch Osteoporos 12:103
Beaudart C, Edwards MH, Moss C et al (2016) English translation and validation of the SarQoL®, a quality of life questionnaire specific for sarcopenia. Age Ageing 0:1–7. https://doi.org/10.1093/ageing/afw192
Beaudart C, Rizzoli R, Bruyère O et al (2014) Sarcopenia: burden and challenges for public health. Arch Public Health 72:45. https://doi.org/10.1186/2049-3258-72-45
Rosenberg IH (1997) Sarcopenia: origins and clinical relevance. J Nutr 127:990S–991S
Mitchell WK, Williams J, Atherton P et al (2012) Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Front Physiol. https://doi.org/10.3389/fphys.2012.00260
Delmonico MJ, Harris TB, Visser M et al (2009) Longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am J Clin Nutr 90:1579–1585. https://doi.org/10.3945/ajcn.2009.28047
Fielding RA, Vellas B, Evans WJ et al (2011) Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 12:249–256. https://doi.org/10.1016/j.jamda.2011.01.003
Morley JE, Abbatecola AM, Argiles JM et al (2011) Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc 12:403–409. https://doi.org/10.1016/j.jamda.2011.04.014
Studenski SA, Peters KW, Alley DE et al (2014) The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci 69:547–558. https://doi.org/10.1093/gerona/glu010
Dupuy C, Lauwers-Cances V, Guyonnet S et al (2015) Searching for a relevant definition of sarcopenia: results from the cross-sectional EPIDOS study. J Cachexia Sarcopenia Muscle 6:144–154. https://doi.org/10.1002/jcsm.12021
Beaudart C, Reginster JY, Slomian J et al (2014) Estimation of sarcopenia prevalence using various assessment tools. Exp Gerontol 61C:31–37. https://doi.org/10.1016/j.exger.2014.11.014
Beaudart C, Reginster J-YY, Slomian J et al (2014) Prevalence of sarcopenia: the impact of different diagnostic cut-off limits. J Musculoskelet Neuronal Interact 14:425–431
Beaudart C, Reginster JYY, Petermans J et al (2015) Quality of life and physical components linked to sarcopenia: The SarcoPhAge study. Exp Gerontol 69:103–110. https://doi.org/10.1016/j.exger.2015.05.003
Roberts HC, Denison HJ, Martin HJ et al (2011) A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing 40:423–429. https://doi.org/10.1093/ageing/afr051
Baumgartner RN, Koehler KM, Gallagher D et al (1998) Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147:755–763
Delmonico MJ, Harris TB, Lee JS et al (2007) Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. J Am Geriatr Soc 55:769–774. https://doi.org/10.1111/j.1532-5415.2007.01140.x
Bijlsma AY, Meskers CG, van Heemst D et al (2013) Diagnostic criteria for sarcopenia relate differently to insulin resistance. Age 35:2367–2375. https://doi.org/10.1007/s11357-013-9516-0
Peña Ordóñez GG, Bustamante Montes LP, Ramírez Duran N et al (2017) Populations and outcome measures used in ongoing research in sarcopenia. Aging Clin Exp Res 29:695–700. https://doi.org/10.1007/s40520-016-0610-x
Reginster J-Y, Cooper C, Rizzoli R et al (2016) Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. Aging Clin Exp Res 28:47–58. https://doi.org/10.1007/s40520-015-0517-y
Landi F, Cesari M, Calvani R et al (2017) The “Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies” (SPRINTT) randomized controlled trial: design and methods. Aging Clin Exp Res 29:89–100. doi: https://doi.org/10.1007/s40520-016-0715-2
Syddall HE, Aihie Sayer A, Dennison EM et al (2005) Cohort profile: the Hertfordshire cohort study. Int J Epidemiol 34:1234–1242. https://doi.org/10.1093/ije/dyi127
van der Pas S, Castell MV, Cooper C et al (2013) European project on osteoarthritis: design of a six-cohort study on the personal and societal burden of osteoarthritis in an older European population. BMC Musculoskelet Disord 14:138. https://doi.org/10.1186/1471-2474-14-138